141 related articles for article (PubMed ID: 33098891)
1. Cytokeratin profiles in pituitary neuroendocrine tumors.
Asa SL; Mete O
Hum Pathol; 2021 Jan; 107():87-95. PubMed ID: 33098891
[TBL] [Abstract][Full Text] [Related]
2. Follicular cells in pituitary neuroendocrine tumors.
Delfin L; Mete O; Asa SL
Hum Pathol; 2021 Aug; 114():1-8. PubMed ID: 33991528
[TBL] [Abstract][Full Text] [Related]
3. Cytokeratins and lung carcinomas.
Nhung NV; Mirejovský P; Mirejovský T; Melínová L
Cesk Patol; 1999 Jul; 35(3):80-4. PubMed ID: 11038661
[TBL] [Abstract][Full Text] [Related]
4. [Cytokeratin expression in the epithelial cells of nasal polyp].
Zhuo M; Yang J; Yang F; Lin X
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Aug; 16(8):397-8. PubMed ID: 12412423
[TBL] [Abstract][Full Text] [Related]
5. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors.
Mete O; Kefeli M; Çalışkan S; Asa SL
Mod Pathol; 2019 Apr; 32(4):484-489. PubMed ID: 30390035
[TBL] [Abstract][Full Text] [Related]
6. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic value of cytokeratins expression in the renal parenchyma tumors.
Alexa A; Baderca F; Lighezan R; Izvernariu D; Raica M
Rom J Morphol Embryol; 2010; 51(1):27-35. PubMed ID: 20191116
[TBL] [Abstract][Full Text] [Related]
8. Cauda Equina Neuroendocrine Tumors: Distinct Epithelial Neuroendocrine Neoplasms of Spinal Origin.
Asa SL; Mete O; Schüller U; Ramani B; Mirchia K; Perry A
Am J Surg Pathol; 2023 Apr; 47(4):469-475. PubMed ID: 36543154
[TBL] [Abstract][Full Text] [Related]
9. Immunocytochemical study of tissues from clinically normal dogs and of neoplasms, using keratin monoclonal antibodies.
Sandusky GE; Wightman KA; Carlton WW
Am J Vet Res; 1991 Apr; 52(4):613-8. PubMed ID: 1711298
[TBL] [Abstract][Full Text] [Related]
10. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.
Chhieng DC; Cangiarella JF; Zakowski MF; Goswami S; Cohen JM; Yee HT
Cancer; 2001 Oct; 93(5):330-6. PubMed ID: 11668468
[TBL] [Abstract][Full Text] [Related]
11. Aberrant keratin expression is common in primary hepatic malignant vascular tumors: A potential diagnostic pitfall.
Lee HE; Torbenson MS; Wu TT; Chandan VS
Ann Diagn Pathol; 2020 Dec; 49():151589. PubMed ID: 32947230
[TBL] [Abstract][Full Text] [Related]
12. Comparison of keratin monoclonal antibodies MAK-6, AE1:AE3, and CAM-5.2.
Listrom MB; Dalton LW
Am J Clin Pathol; 1987 Sep; 88(3):297-301. PubMed ID: 2443001
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin subtyping in chordomas and the fetal notochord: an immunohistochemical analysis of aberrant expression.
Naka T; Iwamoto Y; Shinohara N; Chuman H; Fukui M; Tsuneyoshi M
Mod Pathol; 1997 Jun; 10(6):545-51. PubMed ID: 9195570
[TBL] [Abstract][Full Text] [Related]
14. Keratin subsets and monoclonal antibody HBME-1 in chordoma: immunohistochemical differential diagnosis between tumors simulating chordoma.
O'Hara BJ; Paetau A; Miettinen M
Hum Pathol; 1998 Feb; 29(2):119-26. PubMed ID: 9490269
[TBL] [Abstract][Full Text] [Related]
15. Quantitative expression study of four cytokeratins and p63 in squamous cell carcinoma of the tongue: suitability for sentinel node navigation surgery using one-step nucleic acid amplification.
Yamauchi K; Fujioka Y; Kogashiwa Y; Kohno N
J Clin Pathol; 2011 Oct; 64(10):875-9. PubMed ID: 21705376
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity.
Soukup J; Cesak T; Hornychova H; Manethova M; Michnova L; Netuka D; Vitovcova B; Cap J; Ryska A; Gabalec F
Histopathology; 2021 Sep; 79(3):406-415. PubMed ID: 33738859
[TBL] [Abstract][Full Text] [Related]
17. Pan-cytokeratin markers for rapid frozen section immunocytochemistry from head and facial Mohs cases of basal cell carcinoma: a comparison and evaluation to determine the marker of choice.
Orchard GE; Wojcik K; Shams F; Georgaki E; Quaye CJ; Fernando P; Torres J; Ismail F; Shams M
Br J Biomed Sci; 2015; 72(2):61-6. PubMed ID: 26126321
[TBL] [Abstract][Full Text] [Related]
18. Frequency and extent of cytokeratin expression in paraganglioma: an immunohistochemical study of 60 cases from 5 anatomic sites and review of the literature.
Dermawan JK; Mukhopadhyay S; Shah AA
Hum Pathol; 2019 Nov; 93():16-22. PubMed ID: 31442521
[TBL] [Abstract][Full Text] [Related]
19. The immunophenotype of ependymomas.
Vege KD; Giannini C; Scheithauer BW
Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):25-31. PubMed ID: 10937045
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric analysis of DNA content and keratins by using CK7, CK8, CK18, CK19, and KL1 monoclonal antibodies in benign and malignant human breast tumors.
Ferrero M; Spyratos F; Le Doussal V; Desplaces A; Rouëssé J
Cytometry; 1990; 11(6):716-24. PubMed ID: 1696538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
